May 19, 2014 | Israeli company Enlivex Therapeutics has raised $7 million in a convertible loan from a group of investors. Enlivex, a portfolio company of Hadasit Bio Holdings, is developing cell immunotherapy treatments for Graft versus Host Disease.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments